Elevai Labs, Inc. (ELAB) AI Stock Analysis

Elevai Labs, Inc., based in Newport Beach, California, specializes in the development, manufacturing, and marketing of skincare products in the United States. Established in 2020 and formerly known as Reactive Medical Labs Inc. until December 2021, the company caters to dermatologists, plastic surgeons, medical spa owners, and aesthetic physicians. Its core product lineup features Empower and Enfinity, which are advanced post-procedure serums formulated for the face, neck, and upper chest regions to enhance and prolong treatment benefits. Elevai Labs employs 32 people and works through strategic partnerships to distribute its physician-focused formulations.

Elevai Labs grew annual revenue from $827 in FY2021 to $2.5M in FY2024 before revenue declined 76.1% to $590,084 in FY2025. Across the 4-year period from FY2021 to FY2025, revenue posted a compound annual growth rate of 416.8%. Net losses expanded from -$784,739 in FY2021 to -$7.7M in FY2025, resulting in an FY2025 net margin of -1306.3% and an operating margin of -1250.1%. For the trailing twelve months ended June 30, 2026, revenue stood at $2.6M with an operating margin of -290.0% and an eps of -$1748.36. Quarterly revenue fell 45.8% year-over-year in the latest quarter.

As of June 30, 2026, Elevai Labs held $18.8M in cash and short-term investments against $13.9M in total debt, yielding net cash of $4.9M. Total assets were $36.6M, shareholders' equity reached $16.7M, and the current ratio stood at 1.36. The debt-to-equity ratio was 0.83. Cash flow remains constrained by ongoing deficits, with operating cash flow at -$5.9M and free cash flow at -$6.4M in FY2025. In FY2025, the company deployed $448,255 toward capital expenditures and spent $179 on share buybacks.

Elevai Labs has a market capitalization of $2.2M and an enterprise value of -$886,543. The stock trades at a price-to-sales multiple of 0.9x, compared to 4.1x for the median of its US-listed Healthcare peers. Its price-to-book ratio is 0.2x, while EV to revenue is 0.1x. Over the past year, the stock recorded a return of -99.9%, underperforming the S&P 500 benchmark return of 16.8%. The stock traded at $2.77 on October 16, 2026, sitting 94.6% below its 200-day moving average.

Wall Street analyst ratings, consensus price targets, and forward earnings estimates are not published for Elevai Labs. The company's next earnings report is scheduled for November 13, 2026. The company reported trailing twelve-month eps of -$1748.36 following an FY2025 eps of -$186225.67. Insider ownership accounts for 5.6% of outstanding shares, institutional ownership stands at 3.3%, and short interest represents 3.4% of the float.

This page is an AI-written research summary of Elevai Labs, Inc. (ELAB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ELAB income statement, ELAB balance sheet, ELAB key metrics, ELAB chart. See the ELAB stock overview for the latest quote and news.